Rare Disease in 2026: What Investors Expect and How Companies Must Evolve

In 2026, rare disease investors are prioritizing more than promising science. From commercial readiness to clear revenue pathways, expectations are shifting — and companies must evolve to secure funding and long-term growth.

Forecasting Through an Uncertain Access Environment

Market access uncertainty is reshaping how life sciences companies forecast revenue and plan for launch. As pricing pressure, policy changes, and payer dynamics evolve, commercial teams must adopt more agile, data-driven forecasting strategies to stay competitive.

New Product Planning: Am I Doing It Right?

Planning a new product launch can be challenging. From assessing market needs to aligning cross-functional teams, companies must follow proven strategies to ensure a smooth, successful launch that meets commercial and compliance expectations.